Back to Search Start Over

Takeda Licenses Innate Pharma Antibodies for Celiac Disease Research Program

Source :
M2 Pharma. April 4, 2023
Publication Year :
2023

Abstract

M2 PHARMA-April 4, 2023-Takeda Licenses Innate Pharma Antibodies for Celiac Disease Research Program (C)2023 M2 COMMUNICATIONS - France-based biotechnology company Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) has entered [...]

Subjects

Subjects :
Euronext Paris S.A. -- Licensing agreements
Celiac disease
Medical research
Medicine, Experimental
Biological products -- Licensing agreements
Viral antibodies
Antibodies
Securities industry -- Licensing agreements
Pharmaceutical industry -- Licensing agreements
Securities industry
Company licensing agreement
Chemistry

Details

Language :
English
Database :
Gale General OneFile
Journal :
M2 Pharma
Publication Type :
News
Accession number :
edsgcl.744255934

Tools

Authors Abstract Subjects Details